FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

UIVID APP	KOVAL					
OMB Number:	3235-0287					
Estimated average burden						
hours per response:	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Stromatt Scott C						2. Issuer Name and Ticker or Trading Symbol Aptevo Therapeutics Inc. [APVO]								eck all applica Director	,		10% Ow	ner
(Last) (First) (Middle) 2401 4TH AVENUE, SUITE 1050					3. Date of Earliest Transaction (Month/Day/Year) 03/09/2018							2	X Officer (give title Other (specify below) Chief Medical Officer and SVP					
(Street) SEATTL (City)		7A tate)	98121 (Zip)	n Doriu		4. If Amendment, Date of Original Filed (Month/Day/Year) ative Securities Acquired, Disposed of, or Benefic						Line	5. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
1. Title of Security (Instr. 3) 2. Trans. Date			sactio			3. Transaction Code (Instr. 8) 4. Securities Al Disposed Of (D		es Acquired Of (D) (Instr.	(A) or	5. Amount of		Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)				
Common Stock 03/0				03/09	9/20	9/2018		Code	v	Amount 13,892	(A) or (D)	Price (1)	Transaction (Instr. 3 and 204,	d 4)		D		
			Table II -								osed of, o convertib			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Yea		ransa ode (I	nsaction De Se Ac Dis (D)		Derivative		6. Date Exercisa Expiration Date (Month/Day/Year		te of Securities		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficia Owned Following Reported	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Co	ode	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares		Transacti (Instr. 4)	ion(s)		
Employee Stock Options (Right to Buy)	\$3.13	03/09/2018			A		67,400		(2)		03/09/2028	Common Stock	67,400	\$0	67,40	00	D	
Restricted	(1)	03/09/2018			M			13,892	(3)		(3)	Common	13,892	\$0	16,26	59	D	

Explanation of Responses:

- 1. Each RSU converts into the Issuer's common stock on a one-for-one basis.
- 2. On March 9, 2018, the reporting person was granted 67,400 stock options vesting in three equal annual installments beginning on the first anniversary of the grant date.
- 3. The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 10, 2015. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016, each RSU was adjusted and assumed by the Issuer. The RSUs fully vested as of March 9, 2018.

/s/ Benjamin J. Stein, attorneyin-fact

03/13/2018

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.